Why did the cluster form in Basel of all places?
What is the Basel Area?
The Basel Area is not a political unit but the economic region of the cantons Basel-Stadt, Basel-Landschaft and Jura, marketed jointly by the promotion agency BaselArea.swiss. Industry thinks of the region across the national border: Alsace and southern Baden belong to the same labour market.
Basel became a pharmaceutical location because it was a chemical location first. From 1860 companies on the Rhine produced synthetic dyes; water power, the Rhine port and proximity to France and Germany made the site logistically attractive. The dye works turned into Ciba, Geigy, Sandoz and Hoffmann-La Roche.
Two turning points cemented the position. First, Switzerland had no effective substance patent protection until 1907, which let Basel firms rebuild processes patented in Germany and accumulate capital. Second, the capital stayed in the region: the 1996 merger of Ciba-Geigy and Sandoz into Novartis, and the Roche family shareholders, kept headquarters, research and group functions in Basel rather than moving them.
Who is in the region today?
The core is Roche, with its headquarters and the Bau 1 and Bau 2 towers in Kleinbasel, and Novartis with the St. Johann campus. Around them sit Lonza, Bachem in Bubendorf, Idorsia in Allschwil, Basilea in Allschwil, Mepha in Basel, the University of Basel and ETH Zurich's Department of Biosystems, which is located in Basel.
More important than the large names is the depth: contract manufacturers, sterile fillers, analytical laboratories, packaging specialists, regulatory consultancies and recruiters sit within the same radius. Start a project in Basel and you find suppliers and specialists without budgeting travel time. That is the actual cluster effect.
One common misunderstanding: Swissmedic is not in Basel, it is in Bern. The Federal Office of Public Health (FOPH), which decides on admission to the specialities list, is also in Bern. Proximity to the cluster is no substitute for a relationship with the authorities.
| Company | Site | Focus |
|---|---|---|
| Roche | Basel (BS) | Headquarters, oncology, diagnostics, research |
| Novartis | Basel (BS), St. Johann campus | Headquarters, research, group functions |
| Lonza | Basel (BS), Visp (VS) | CDMO, biologics, active ingredients |
| Bachem | Bubendorf (BL) | Peptides and oligonucleotides |
| Idorsia | Allschwil (BL) | Research-based pharma, successor to Actelion |
| Basilea Pharmaceutica | Allschwil (BL) | Anti-infectives |
| Mepha Pharma | Basel (BS) | Generics, the largest Swiss generics supplier |
| University of Basel and ETH D-BSSE | Basel (BS) | Life-science research and education |
What is the location good at, and what is it not?
The cluster delivers specialists, suppliers and investors at short distance, plus an international airport and Rhine shipping for chemicals. What it does not deliver is cheap floor space, cheap staff or free capacity in sterile production. Plan a factory and Basel charges top prices.
Practice therefore often splits the work: group functions, regulatory and business development in Basel or Zug, manufacturing in Aargau, Valais or Ticino, logistics with a wholesaler in the Mittelland. For a country organisation of ten people Basel is a good choice; for a plant of three hundred it is rarely the cheapest.
- Strengths: density of specialists, supplier network, proximity to investors, tri-national labour market with Alsace and southern Baden
- Strengths: short distances to contract manufacturers, testing laboratories and regulatory consultants
- Weaknesses: high salaries and rents, competition for experienced staff with Roche and Novartis
- Weaknesses: tight sterile capacity, long lead times on construction projects
- Neutral: proximity to the authorities gains nothing, because Swissmedic and the FOPH are in Bern
What does a market entry in the region need?
A site in Basel does not replace an authorisation. To reach the Swiss market a foreign manufacturer needs an authorisation holder domiciled or represented in Switzerland, an establishment licence from Swissmedic depending on the activity, and a responsible person with technical qualifications. A Basel address is a location choice, not a regulatory step.
The region makes sense when you are after research collaboration, licensing business or contract manufacturing. For pure market access one partner who bundles authorisation, licence and distribution is often enough, whatever canton that partner sits in.
- Clarify the goal: research site, group function, manufacturing or pure market access
- Choose the canton on cost structure and function, not on prestige
- Settle the authorisation holder and the establishment licence independently of the site
- Approach suppliers and contract manufacturers before choosing the site, capacity is the bottleneck
- If reimbursement is the aim, plan the FOPH pricing dossier from the start
Frequently asked questions
Which pharmaceutical companies are in Basel?
Basel-Stadt and Basel-Landschaft host Roche, Novartis, Lonza, Mepha Pharma, Bachem in Bubendorf, Idorsia and Basilea Pharmaceutica in Allschwil, as well as Alcon and Straumann, among others. This directory lists every recorded company in the two cantons on the canton pages.
Is Basel Europe's largest pharmaceutical location?
Measured by value added per inhabitant and by the density of pharmaceutical headquarters, the region counts as one of Europe's leading clusters. In absolute employment terms, metropolitan regions such as Rhine-Main or Ireland's manufacturing cluster are comparable in size. What sets Basel apart is the combination of headquarters, research and suppliers in a small area.
Do I need a presence in Basel for the Swiss market?
No. What counts for market access is an authorisation holder domiciled or represented in Switzerland, not the canton. Many successful market entries use a partner in the Mittelland or in Ticino. Basel pays off mainly for research, licensing business and group functions.
Do Alsace and southern Baden belong to the Basel Area?
Economically yes, legally no. The labour market is tri-national and many employees commute from France and Germany. For authorisation, establishment licence and market access, however, only Swiss law applies as soon as a product is placed on the Swiss market.